Leonabio, Inc. current report, 27 May 2021

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Athira Pharma, Inc. (noting a discrepancy in the request metadata which listed "Leonabio, Inc.") regarding events occurring on May 27, 2021. The filing details the results of the Company's 2021 Annual Meeting of Stockholders, which was held virtually.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.

Material Changes and Voting Results

Approximately 67% of the total shares entitled to vote (24,871,871 shares) were present virtually or by proxy. The following proposals were approved:

  • Proposal One (Election of Class I Directors): All three nominees were elected to serve until the 2024 annual meeting.
    • Tadataka Yamada, M.D.: 16,341,870 votes For; 4,067,024 Withheld.
    • Leen Kawas, Ph.D.: 17,972,262 votes For; 2,436,632 Withheld.
    • Barbara Kosacz: 19,961,742 votes For; 447,152 Withheld.
  • Proposal Two (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
    • Votes For: 24,862,289
    • Votes Against: 9,471
    • Abstain: 111

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting vote tallies.

Key Facts for Investor Verification

  • Verify the correct registrant name is Athira Pharma, Inc. (Ticker: ATHA), as the request metadata incorrectly referenced "Leonabio, Inc."
  • Confirm the election of the three Class I directors (Yamada, Kawas, Kosacz) for the term ending in 2024.
  • Note the overwhelming support for the ratification of Ernst & Young LLP as the independent auditor.
  • Review the definitive proxy statement filed on April 16, 2021, for detailed background on the director nominees and auditor appointment.